Literature DB >> 12126957

Hypoxia stimulates p16 expression and association with cdk4.

Adam Zygmunt1, Vivienne C Tedesco, Eshwar Udho, Nancy A Krucher.   

Abstract

Exposure of CV-1P cells to hypoxic conditions causes cell proliferation inhibition concomitant with the accumulation of pRb in the hypophosphorylated, growth suppressive form. This is in part due to inhibition of pRb-directed cdk4 and cdk2 activity. In this study we attempted to elucidate the mechanism by which cdk4 is inactivated under hypoxic conditions. After 18 h of hypoxia, CV-1P cells are inhibited from progressing from G(1) phase into the S phase of the cell cycle. This occurs in conjunction with dephosphorylation of serine-795, which is a putative substrate of cdk4. The amounts of cdk4, cdk6, and the D type cyclins are not affected by 18 h of hypoxia. The levels of cdki p16, p18, p19, and p57 under aerobic or hypoxic conditions were analyzed and although the levels of most cdki are unaffected by hypoxic conditions, the level of p16 increases significantly by 18 h of hypoxia. The mechanism by which cdk4 activity is inhibited under hypoxic conditions may be mediated through p16 association with cdk4. Immunoprecipitation analysis shows that p16 binds to cdk4 under hypoxic conditions but does not in cells maintained under aerobic conditions. Thus p16 may be involved in hypoxia-induced growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126957     DOI: 10.1006/excr.2002.5564

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells.

Authors:  Heidi Högel; Krista Rantanen; Terhi Jokilehto; Reidar Grenman; Panu M Jaakkola
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

Review 2.  Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.

Authors:  Rebecca A Sager; Sarah J Backe; Elham Ahanin; Garrett Smith; Imad Nsouli; Mark R Woodford; Gennady Bratslavsky; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Nat Rev Urol       Date:  2022-03-09       Impact factor: 16.430

3.  Myc down-regulation affects cyclin D1/cdk4 activity and induces apoptosis via Smac/Diablo pathway in an astrocytoma cell line.

Authors:  D Amendola; M De Salvo; R Marchese; C Verga Falzacappa; A Stigliano; E Carico; E Brunetti; M Moscarini; B Bucci
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

4.  Obstructive sleep apnea, nighttime arousals, and leukocyte telomere length: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Judith E Carroll; Michael R Irwin; Teresa E Seeman; Ana V Diez-Roux; Aric A Prather; Richard Olmstead; Elissa Epel; Jue Lin; Susan Redline
Journal:  Sleep       Date:  2019-07-08       Impact factor: 6.313

5.  hYSK1 promotes cancer cell proliferation and migration through negative regulation of p16INK4a under hypoxic conditions.

Authors:  Mee-Hyun Lee; Zigang Dong; Young-Joon Surh; Bu Young Choi
Journal:  Oncotarget       Date:  2017-10-06

6.  Quercetin protects PC-12 cells against hypoxia injury by down-regulation of miR-122.

Authors:  Rui Yan; Huiling Tian; Zhongxiu Du
Journal:  Iran J Basic Med Sci       Date:  2019-04       Impact factor: 2.699

7.  The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer.

Authors:  Emmi Peurala; Peppi Koivunen; Kirsi-Maria Haapasaari; Risto Bloigu; Arja Jukkola-Vuorinen
Journal:  Breast Cancer Res       Date:  2013-01-21       Impact factor: 6.466

8.  Hypoxia inducible prolyl hydroxylase PHD3 maintains carcinoma cell growth by decreasing the stability of p27.

Authors:  Heidi Högel; Petra Miikkulainen; Lucia Bino; Panu M Jaakkola
Journal:  Mol Cancer       Date:  2015-07-30       Impact factor: 27.401

9.  The 5'-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding.

Authors:  Alessandra Bisio; Elisa Latorre; Virginia Andreotti; Brigitte Bressac-de Paillerets; Mark Harland; Giovanna Bianchi Scarra; Paola Ghiorzo; Robert C Spitale; Alessandro Provenzani; Alberto Inga
Journal:  Oncotarget       Date:  2015-11-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.